Inbec治疗效果好吗？

Trimax contains three ingredients: abacavir, lamivudine and dolutegravir. Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs); dolutegravir is an integrase inhibitor (INIs). Existing research shows that one year (48 weeks) after HIV-infected patients were treated with Inbec, 93% of the infected people's viral load became negative.

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle).

Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted into the active metabolite carbavir triphosphate (CBV-TP), a deoxyguanosine-5'-triphosphate (dGTP) analogue, under the action of intracellular enzymes. CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) by competing with the natural substrate dGTP and inserting into viral DNA.

Lamivudine is a synthetic nucleoside analogue. Lamivudine is phosphorylated in cells to generate the active 5-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The main mode of action of 3T-CTP is to terminate DNA chain synthesis by inserting nucleotide analogs, thereby inhibiting RT activity.

In 2018, GSK launched the integrase DTG (Inbec) in China. This therapeutic agent has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. This time, Inbec uses DTG, an integrase inhibitor, as the core drug, coupled with a treatment plan of two backbone drugs, abacavir and lamivudine, and made a single-tablet treatment for promotion, making the core drug a great progress in HAART treatment.

Suimeikai () was approved by the FDA on August 27, 2014. On January 20, 2018, ViiV, a joint venture of GlaxoSmithKline, launched Inbec, the first complete antiviral treatment plan with dolutegravir (also known as DTG in English) as the core, officially launched in China. This is also the first complete single-pill compound treatment plan in the field of HIV treatment in China.